A recent research has found that Botox (a bladder injection of botulinum toxin) could help in controlling bladder incontinence, after the first and second-line therapies proved inadequate.
A head-to-head comparison of sacral neuromodulation that (an implanted device sold as InterStim), or and botulinum toxin shows that Botox provides more daily relief for women, but might also be associated with more adverse events.
Botox in the bladder muscle works to address urgency urinary incontinence by relaxing the overactive bladder muscles that cause the condition.
A sacral neuromodulation implant does the same thing by sending electrical pulses to nerves in the spine.
The study's lead author Cindy L. Amundsen said, "Urgency urinary incontinence is common, with 17 percent of women over age 45 and 25 percent of women over age 75 suffering from it. That's why it's important for both patients and health care providers to have information that can guide their choice between these two therapies."
The study involved 381 women from nine U.S. medical centers, who recorded at least six urgency incontinent episodes over three consecutive days and had not improved with other treatments.
More From This Section
The participants were randomly assigned to either receive sacral neuromodulation or a 200-unit injection of botulinum toxin.
After a trial period to test their responsiveness to the therapies, 364 women were enrolled and followed for six months after treatment.
The team analyzed the number of urgency incontinent episodes on monthly "bladder diaries."
Participants who received botulinum toxin saw their number of daily urgency incontinent episodes decrease by 3.9 on average versus 3.3 on average in the sacral neuromodulation group.
The difference was statistically significant.
Botulinum toxin participants also reported a greater reduction in bothersome symptoms, higher satisfaction with treatment and a greater likelihood of endorsing the treatment.
Additionally, among participants, who completed at least four monthly diaries, a higher percentage of botulinum toxin participants saw at least a 75-percent reduction in or complete resolution of urgency incontinent symptoms.
However, the Botox patients also had three times the rate of urinary tract infections.
Some botulinum toxin participants also required intermittent self-catheterization, although at lower rates than reported in previous studies using this dose.
For the sacral neuromodulation participants, the most common adverse event was removal or revision of the implant during the six months.
This occurred at a low rate, similar to previous studies.
"This study is valuable because it is the first randomized trial comparing the efficacy of two FDA-approved, third-line therapies in a severely affected population. The information should help guide care," Amundsen said.
While the study did not compare the cost of the two treatments, patients, who receive botulinum toxin may require additional injections as part of continued treatment.
Additionally, the study only takes Botox into account and no conclusions can be drawn for other botulinum toxin preparations that may be used to treat urgency incontinence.
The findings were published in the Journal of the American MedicalAssociation (JAMA).